DRTS · Alpha Tau Medical Ltd. · Stock research

Current Thesis

The catalyst gap flagged in the prior note closed faster than expected, and it closed upward. On 2026-08-10 Alpha Tau reported Q2 with $104.8M in cash, equivalents and deposits at 2026-06-30 (versus $76.9M at 2025-12-31), disclosed the first interim readout from REGAIN in recurrent glioblastoma, and registered for a dual listing on the Tel Aviv Stock Exchange. HC Wainwright raised its target to $16 from $15 on 2026-08-11. The adjusted daily series puts the 2026-08-21 close at $14.92, which is the 52-week high itself, up 48.6% over three months with RSI(14) at 78.5. The leg an investor is buying is the platform re-rating: Alpha DaRT moving from one pivotal skin-cancer trial to a multi-indication file — cSCC (ReSTART, 88 patients enrolled), glioblastoma (REGAIN), pancreatic (IMPACT) — funded past the readout and with a US commercial partner already on the cap table. What is missing is timing. The 2026-08-10 update guided ReSTART top-line to "late 2026 or early 2027", a widening from the earlier late-H2-2026 language, so the registrational datapoint that actually validates the modular PMA is not inside this quarter. The narrative is accelerating — dated by the 2026-08-21 new high, the 2026-08-11 target raise and the fresh 2026-08-10 REGAIN and TASE headlines — but accelerating from an extended price with no registrational event in the next 30 days.

Bullish and bearish views on Alpha Tau Medical Ltd.

The model's bull view on Alpha Tau Medical Ltd. (DRTS), in brief: Balance sheet is no longer the constraint. The bear view: The loss line is ugly and unreconciled. The company release reports a Q2 2026 net loss of $68.8M, or $0.76 per share, against $18.8M ($0.25) in Q2 2025. Benzinga's 2026-08-10 earnings item recorded EPS of -$0.50 versus a -$0.14 consensus. Cash rose over the same six months… Both cases follow in full.

Bull Case

• Balance sheet is no longer the constraint. Cash, equivalents, short-term and restricted deposits of $104.8M at 2026-06-30 against $76.9M at 2025-12-31 (Q2 2026 results, 2026-08-10). The build spans the ~$35M Tolmar upfront announced 2026-06-03. Six-month R&D of $20.9M versus $14.2M a year earlier shows the spend going into trials rather than overhead.
• A second indication produced data, not just enrollment. REGAIN recurrent glioblastoma interim, disclosed 2026-08-10: first three patients, 100% local disease control, 67% complete response (two CRs, one stable disease with 30% tumour reduction), one grade 3 serious adverse event that resolved with steroids. Three patients is a signal of feasibility, not efficacy — but it is a new indication with a live dataset.
• The pivotal is fully enrolled and the regulatory file is open. ReSTART US multi-centre pivotal in recurrent cSCC enrolled 88 patients (enrollment completed 2026-05-08); the first module of the modular PMA went to FDA in January 2026. Approval risk remains, but the submission machinery is running.
• Sell-side moved up after the miss, not down. HC Wainwright maintained Buy and raised the target to $16 on 2026-08-11, the session after a headline EPS miss — the analyst response keyed off cash and pipeline rather than the loss line.
• The shareholder base is being widened by design. TASE dual-listing registration on 2026-08-10 covers more than 146 million ordinary shares including those underlying options, warrants and employee plans, under English ticker DRTS. Israeli institutional access is a distribution channel a US-only micro cap does not have.

Bear Case

• The loss line is ugly and unreconciled. The company release reports a Q2 2026 net loss of $68.8M, or $0.76 per share, against $18.8M ($0.25) in Q2 2025. Benzinga's 2026-08-10 earnings item recorded EPS of -$0.50 versus a -$0.14 consensus. Cash rose over the same six months, which implies a large non-cash component, but nothing in the material cited here itemizes it — a reader should treat the quarter's true operating burn as unresolved until the 6-K detail is read.
• The registrational date got looser, not tighter. "Late 2026 or early 2027" (2026-08-10) replaces the previous late-H2-2026 framing. The prior note listed exactly this — a Q2 update pushing ReSTART into 2027 — as the observable for catalyst-gap risk. It half-triggered, and the stock made new highs anyway.
• Three patients is three patients. The REGAIN interim and the July HNSCC combination result (100% ORR across nine evaluable patients, 18.2-month median OS, 2026-07-21) are both small, single-arm and selected. Neither de-risks the cSCC primary endpoint.
• Insider supply stepped up with the price. CFO Raphi Levy sold 17,730 shares at an average of $14.00 on 2026-08-11 under a Rule 10b5-1 plan, leaving 90,180 shares directly held. The plan is pre-arranged, so this is not a discretionary read on value — but the size is roughly eight times the July cadence and it printed into the high.
• Still pre-revenue. No US-approved product; consensus revenue for the quarter was in the low hundreds of thousands of dollars. Every dollar of the market cap is trial and regulatory progress.

Setup & Price Structure

The 2026-08-21 close of $14.92 is the 52-week high, 0.0% below it, after a three-month advance of 48.6%. RSI(14) at 78.5 is the highest reading in the covered period — the 2026-08-07 close of $13.14 carried RSI 47.0 with price 3.2% under the then-high of $13.57. The Q2 print therefore did two things at once: it broke a two-week range and it consumed most of the distance to the only current published target, HC Wainwright's $16 (2026-08-11). Crowding observables, stated plainly: price at the high with RSI 78.5; a three-month move of +48.6%; an officer selling roughly eight times his July size on 2026-08-11; a registration statement covering 146M+ shares including option and warrant underliers; average daily volume near 1M shares, which is why single clinical headlines have produced double-digit sessions in both directions. There is no earnings date inside the next 30 days to force a resolution.

Catalyst Calendar (next 30 days)

• Nothing confirmed with a fixed date before 2026-09-21. The Q2 print (2026-08-10) is spent and Q3 results are not scheduled; the Q1/Q2 cadence (2026-05-18, 2026-08-10) points to mid-November.
• ~2026-09-30 (est.) — IMPACT pancreatic trial recruitment completion, guided to Q3 2026 in the 2026-08-10 corporate update. A completion announcement is the only company-guided item that could land near the window's edge.
• ~2026-12-31 (est.) — REGAIN glioblastoma enrollment completion guided to H2 2026 with data expected by year-end.
• ~2026-12-31 to ~2027-03-31 (est.) — ReSTART pivotal cSCC top-line, guided 2026-08-10 to "late 2026 or early 2027".

Elapsed catalysts

• TASE trading commencement, date not fixed — registration was announced 2026-08-10; the start of Israeli-session trading has not been dated publicly. (passed 16d ago)

What Would Change Our Mind

The structure that has to hold is the post-Q2 breakout over the prior $13.57 high; losing it means the 2026-08-10 package (cash, REGAIN interim, TASE) was a one-print repricing rather than the start of a platform re-rating. Concretely, a daily close below $13.50 gives that shelf back and puts the $11.99 Tolmar strike back in play as the next reference. Three non-price conditions would independently break the frame: a Q3 update (est. mid-November) that moves ReSTART top-line past Q1 2027 or removes the date entirely; an ATM programme, registered direct or shelf takedown disclosed in a 6-K, which would convert the TASE registration's 146M-share coverage from access into supply; or REGAIN's enrollment-complete dataset showing a complete-response rate materially below the 67% seen in the first three patients. On the upside, the label would firm rather than flip if ReSTART top-line were fixed to a specific date and a second broker initiated with published estimates — analyst coverage is currently thin enough that one voice sets the target.

Correlation Notes

• Clinical-stage micro-cap medtech with no revenue trades on small-cap biotech risk appetite; XBI drawdowns pull names like this regardless of company news, and the 1M-share average volume amplifies the move.
• Israeli-domiciled issuer with operations in Israel: regional risk episodes have historically hit Tel Aviv-linked US listings independent of fundamentals. The 2026-08-10 TASE registration increases that linkage once trading begins, since price discovery would start in the Israeli session before the US open.
• The comparable set is alpha/beta-emitting radiotherapeutics rather than oncology pharma — sentiment in radiopharma peers moves the group's multiple, and read-throughs from any alpha-emitter safety event would be sector-wide.
• Single-analyst target concentration (HC Wainwright, $16 as of 2026-08-11) means broker actions are idiosyncratic events here, not consensus drift.

Positioning & Life-Cycle

The narrative is accelerating, dated by the 2026-08-21 new 52-week high at $14.92, the 2026-08-11 target raise to $16, and the 2026-08-10 cluster of Q2 cash, REGAIN interim and TASE registration. What would date a flip to saturated: retail-sentiment coverage clustering without new company disclosures, further Form 4 sales at or above the 17,730-share size, or a failure to hold $13.57 on the first pullback — the last of which is the same condition as the price break above.